Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.75), $0.11 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $15.72 million.

“Our first quarter results were highlighted by our sales performance, recognition of our #1 customer support services for the 4th consecutive year*, and meaningful progress with our new products in development,” said Kim Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care. “These achievements give us confidence in our ability to accomplish our key goals for this year, and we remain focused on successfully executing our business plan and supporting our growing customer base.”

For the year ending December 31, 2017, the Company is reaffirming its financial guidance as follows:

• Non-GAAP sales are estimated to be in the range of $100 million to $107 million
• Non-GAAP operating margin is estimated to be in the range of negative 70 percent to negative 65 percent, which includes:
  • Approximately $11.0 million in non-cash, stock-based compensation expense
  • Approximately $6.0 million to $7.0 million of depreciation and amortization

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.